Tumors can also modulate cDC1s’ cross-presentation capacity of tumor antigens—through gelsolin secretion in the TME of a melanoma mouse model—by inhibiting F-actin recognition by Clec9α, leading to a decreased proportion of tumor-infiltrating cytotoxic T-cells [69]. Here, CLEC9A is linked to neoplasm.